We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Rewards Shareholders With 18.5% Dividend Increase
Read MoreHide Full Article
In a shareholder-friendly move, Danaher Corporation (DHR - Free Report) has announced a hike in its dividend payout. The company increased its quarterly dividend by 18.5% to 32 cents per share (annually: $1.28). The new dividend will be paid out on April 25, 2025, to shareholders of record as of March 28, 2025.
The move underscores DHR’s sound financial health as it utilizes free cash flow to enhance its shareholders’ returns. Prior to this, Danaher had hiked its dividend by 8% to 27 cents per share in February 2024.
Strong cash flows allow Danaher to effectively deploy capital for making acquisitions, repurchasing shares and paying out dividends. The company’s adjusted free cash flow totaled $5.3 billion in 2024, reflecting an increase of 3.5% year over year. Dividend payments totaled $768 million in 2024 and $821 million in 2023.
The company also bought back 28 million of its common stock for $7 billion in 2024. We believe such disbursements highlight its operational strength and commitment to enhancing shareholders’ wealth.
DHR Zacks Rank & Stock Price Performance
DHR, with a $150.3 billion market capitalization, currently carries a Zacks Rank #4 (Sell). Despite recovery, sluggish demand across the pharma and biotech markets in China has been weighing on Danaher’s Instrument businesses under the Life Sciences segment.
The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end-markets. For the first quarter of 2025, Danaher anticipates core revenues from the Life Sciences segment to decline in mid-single-digits on a year-over-year basis.
DHR Stock Price Performance
Image Source: Zacks Investment Research
In the past six months, the company’s shares have lost 23.1% compared with the medical services industry’s 14.3% decline.
The Zacks Consensus Estimate for its 2025 earnings is pegged at $7.63 per share, down 7.3% from the 30-day-ago figure.
Other Stocks to Consider
Some better-ranked stocks from the same space are discussed below.
Premier, Inc. (PINC - Free Report) presently sports a Zacks Rank #1 (Strong Buy). It surpassed estimates thrice and missed once in the trailing four quarters, delivering an average earnings surprise of 20.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for PINC’s fiscal 2025 (ending June 2025) earnings has inched down 0.8% in the past 30 days.
HealthEquity, Inc. (HQY - Free Report) presently carries a Zacks Rank #2 (Buy). It surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 16.6%.
In the past 60 days, the Zacks Consensus Estimate for HQY’s fiscal 2025 (ending January 2025) earnings has remained stable.
Cencora, Inc. (COR - Free Report) currently carries a Zacks Rank of 2. COR surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 4.9%.
In the past 30 days, the Zacks Consensus Estimate for its fiscal 2025 (ending September 2025) earnings has increased 2%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Danaher Rewards Shareholders With 18.5% Dividend Increase
In a shareholder-friendly move, Danaher Corporation (DHR - Free Report) has announced a hike in its dividend payout. The company increased its quarterly dividend by 18.5% to 32 cents per share (annually: $1.28). The new dividend will be paid out on April 25, 2025, to shareholders of record as of March 28, 2025.
The move underscores DHR’s sound financial health as it utilizes free cash flow to enhance its shareholders’ returns. Prior to this, Danaher had hiked its dividend by 8% to 27 cents per share in February 2024.
Strong cash flows allow Danaher to effectively deploy capital for making acquisitions, repurchasing shares and paying out dividends. The company’s adjusted free cash flow totaled $5.3 billion in 2024, reflecting an increase of 3.5% year over year. Dividend payments totaled $768 million in 2024 and $821 million in 2023.
The company also bought back 28 million of its common stock for $7 billion in 2024. We believe such disbursements highlight its operational strength and commitment to enhancing shareholders’ wealth.
DHR Zacks Rank & Stock Price Performance
DHR, with a $150.3 billion market capitalization, currently carries a Zacks Rank #4 (Sell). Despite recovery, sluggish demand across the pharma and biotech markets in China has been weighing on Danaher’s Instrument businesses under the Life Sciences segment.
The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end-markets. For the first quarter of 2025, Danaher anticipates core revenues from the Life Sciences segment to decline in mid-single-digits on a year-over-year basis.
DHR Stock Price Performance
Image Source: Zacks Investment Research
In the past six months, the company’s shares have lost 23.1% compared with the medical services industry’s 14.3% decline.
The Zacks Consensus Estimate for its 2025 earnings is pegged at $7.63 per share, down 7.3% from the 30-day-ago figure.
Other Stocks to Consider
Some better-ranked stocks from the same space are discussed below.
Premier, Inc. (PINC - Free Report) presently sports a Zacks Rank #1 (Strong Buy). It surpassed estimates thrice and missed once in the trailing four quarters, delivering an average earnings surprise of 20.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for PINC’s fiscal 2025 (ending June 2025) earnings has inched down 0.8% in the past 30 days.
HealthEquity, Inc. (HQY - Free Report) presently carries a Zacks Rank #2 (Buy). It surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 16.6%.
In the past 60 days, the Zacks Consensus Estimate for HQY’s fiscal 2025 (ending January 2025) earnings has remained stable.
Cencora, Inc. (COR - Free Report) currently carries a Zacks Rank of 2. COR surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 4.9%.
In the past 30 days, the Zacks Consensus Estimate for its fiscal 2025 (ending September 2025) earnings has increased 2%.